Allaire Manon, Da Fonseca Leonardo G, Sanduzzi-Zamparelli Marco, Choi Won-Mook, Monge Cecilia, Liu Ken, Leibfried Michael, Manes Sarah, Maravic Zorana, Mishkovikj Milan, Bruix Jordi, Reeves Helen L, Salem Riad, Sangro Bruno
AP-HP Sorbonne Université, Hôpital Universitaire Pitié-Salpêtrière, Service d'Hépato-gastroentérologie, Paris, France.
INSERM UMR 1138, Centre de recherche des Cordeliers, Paris, 75006, France.
Lancet Reg Health Eur. 2025 Jul 31;57:101408. doi: 10.1016/j.lanepe.2025.101408. eCollection 2025 Oct.
Hepatocellular carcinoma (HCC) is a major cause of cancer deaths worldwide. It is often diagnosed at advanced stages, requiring systemic therapies like sorafenib, lenvatinib, atezolizumab-bevacizumab, and tremelimumab-durvalumab. However, disparities in access to systemic therapies for HCC remain a major global challenge, particularly in low- and middle-income countries where high drug costs, regulatory delays, and limited healthcare infrastructure impede treatment. Drawing on international experience, we highlight the urgent need for coordinated advocacy and innovative programs-such as Project Orbis and expedited approval pathways-to improve drug availability. Multisectoral collaboration among patient groups, clinicians, policymakers, and industry is essential to ensure equitable access to life-saving therapies and to reduce the burden of HCC worldwide.
肝细胞癌（HCC）是全球癌症死亡的主要原因。它通常在晚期被诊断出来，需要索拉非尼、仑伐替尼、阿替利珠单抗-贝伐单抗和曲美木单抗-度伐利尤单抗等全身治疗。然而，获得HCC全身治疗的差异仍然是一个重大的全球挑战，特别是在低收入和中等收入国家，高药价、监管延误和有限的医疗基础设施阻碍了治疗。借鉴国际经验，我们强调迫切需要进行协调宣传和开展创新项目，如“奥比斯计划”和加快审批途径，以提高药物可及性。患者群体、临床医生、政策制定者和行业之间的多部门合作对于确保公平获得挽救生命的治疗方法以及减轻全球HCC负担至关重要。
